- Home
- CADL vs SLN Comparison
CADL vs SLN Comparison
Compare CADL & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- SLN
- Stock Information
- Founded
- CADL 1999
- SLN 1994
- Country
- CADL United States
- SLN United Kingdom
- Employees
- CADL N/A
- SLN N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- SLN Health Care
- Exchange
- CADL Nasdaq
- SLN Nasdaq
- Market Cap
- CADL 306.4M
- SLN 352.2M
- IPO Year
- CADL 2021
- SLN N/A
- Fundamental
- Price
- CADL $11.63
- SLN $4.79
- Analyst Decision
- CADL Strong Buy
- SLN Buy
- Analyst Count
- CADL 4
- SLN 4
- Target Price
- CADL $19.75
- SLN $46.25
- AVG Volume (30 Days)
- CADL 1.2M
- SLN 334.1K
- Earning Date
- CADL 03-27-2025
- SLN 02-27-2025
- Dividend Yield
- CADL N/A
- SLN N/A
- EPS Growth
- CADL N/A
- SLN N/A
- EPS
- CADL N/A
- SLN N/A
- Revenue
- CADL N/A
- SLN $21,773,221.00
- Revenue This Year
- CADL N/A
- SLN N/A
- Revenue Next Year
- CADL N/A
- SLN $104.98
- P/E Ratio
- CADL N/A
- SLN N/A
- Revenue Growth
- CADL N/A
- SLN N/A
- 52 Week Low
- CADL $1.34
- SLN $4.06
- 52 Week High
- CADL $14.60
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- CADL 72.95
- SLN 41.33
- Support Level
- CADL $8.11
- SLN $4.71
- Resistance Level
- CADL $13.68
- SLN $5.16
- Average True Range (ATR)
- CADL 0.78
- SLN 0.47
- MACD
- CADL 0.42
- SLN 0.08
- Stochastic Oscillator
- CADL 70.29
- SLN 32.74
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.